ArticleHepatobiliary surgery and nutrition2026
Long-term outcome of hepatectomy following conversion therapy for initially unresectable hepatocellular carcinoma versus direct hepatectomy for early-stage hepatocellular carcinoma.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although emerging evidence has reported the efficacy and safety of sequential surgery following targeted and immunotherapy conversion treatment for patients with initially unresectable hepatocellular carcinoma (HCC), these studies have been limited by small sample sizes and short follow-up periods. Moreover, whether such patients can achieve comparable survival outcomes to those undergoing upfront surgery for early-stage resectable HCC remains unreported. This study aims to compare long-term survival between patients with initially unresectable HCC who underwent sequential surgery after conversion therapy and those with early-stage HCC who received direct surgery. Methods: The retrospective cohort study was conducted from December 2018 through December 2023, with follow-up ending in June 2024. Ninety-nine patients with initially unresectable HCC underwent conversion therapy based on immune checkpoint inhibitors and anti-angiogenic targeted drugs, with a median duration of five cycles, followed by radical hepatectomy. One hundred and eleven patients with Barcelona Clinical Liver Cancer (BCLC) stage A HCC only underwent direct hepatectomy. Clinical characters, surgical features and survival outcomes of the two groups were compared. Results: In this cohort study of 210 patients, the 1-, 3-, and 5-year overall survival (OS) rates of initially unresectable HCC patients who underwent radical hepatectomy after achieving either partial response (PR) or complete response (CR) were comparable to those of early-stage (BCLC-A) HCC patients who received direct hepatectomy (100% Conclusions: For patients with initially unresectable HCC, radical hepatectomy after effective conversion therapy (defined as achieving either PR or CR by mRECIST) brings a satisfying long-term outcome that is comparable to BCLC-A HCC patients undergoing direct surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.